UK markets closed
  • NIKKEI 225

    30,240.06
    -8.75 (-0.03%)
     
  • HANG SENG

    24,208.78
    +16.62 (+0.07%)
     
  • CRUDE OIL

    75.42
    +1.44 (+1.95%)
     
  • GOLD FUTURES

    1,750.40
    -1.30 (-0.07%)
     
  • DOW

    34,869.37
    +71.37 (+0.21%)
     
  • BTC-GBP

    31,242.12
    -622.54 (-1.95%)
     
  • CMC Crypto 200

    1,059.64
    -41.88 (-3.80%)
     
  • ^IXIC

    14,969.97
    -77.73 (-0.52%)
     
  • ^FTAS

    4,067.82
    +5.62 (+0.14%)
     

Adamas to Announce Second Quarter Financial Results and Host Conference Call on August 9, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

EMERYVILLE, Calif., August 02, 2021--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report second quarter 2021 financial results on Monday, August 9, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Investor Conference Call and Webcast

The conference call can be accessed by dialing 1-877-407-9716 for participants in the U.S. or Canada and 1-201-493-6779 for international callers. All callers must provide the following Conference ID: 13720109. The webcast can be accessed live via the investor section of the Adamas website at https://ir.adamaspharma.com/events-presentations and will be available for replay for approximately 30 days.

About Adamas Pharmaceuticals, Inc.

At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210802005659/en/

Contacts

Media:
Sarah Mathieson
Vice President of Corporate Communications
510-450-3528
smathieson@adamaspharma.com

Investors:
Peter Vozzo
Managing Director, Westwicke
443-213-0505
peter.vozzo@westwicke.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting